Bicycle Therapeutics plc (BCYC)
After hours:
| Previous close | 24.49 |
| Open | 24.16 |
| Bid | 23.30 x 100 |
| Ask | 23.47 x 100 |
| Day's range | 23.06 - 24.61 |
| 52-week range | 12.54 - 28.91 |
| Volume | |
| Avg. volume | 401,019 |
| Market cap | 890.333M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.08 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 43.20 |
- Business Wire
Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, England & BOSTON, April 02, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024, at 11 a.m. ET.
- Business Wire
Bicycle Therapeutics to Present at the AACR Annual Meeting 2024
CAMBRIDGE, England & BOSTON, March 05, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of three abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego on April 5-10.
- Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, England & BOSTON, February 28, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following investor conferences in March:
